2
RESEARCH METHODOLOGY
33
5
MARKET OVERVIEW
Emerging biologics and smart drug delivery tech redefine patient-centric, minimally invasive healthcare markets.
54
5.2.1.1
RISING PREVALENCE OF CHRONIC DISEASES
5.2.1.2
GROWING ADOPTION OF BIOLOGICS AND VACCINES
5.2.1.3
HIGH R&D INVESTMENTS FROM GOVERNMENT ORGANIZATIONS AND PRIVATE BODIES
5.2.1.4
SHIFT TOWARD PERSONALIZED MEDICINES AND PATIENT-CENTRIC CARE
5.2.1.5
RISING POPULARITY OF SELF-ADMINISTERED MEDICINES
5.2.2.1
STRINGENT REGULATORY POLICIES AND COMPLIANCE HURDLES
5.2.2.2
FOCUS ON ALTERNATIVE DRUG DELIVERY METHODS
5.2.3.1
INCREASED PREFERENCE FOR MINIMALLY INVASIVE PRODUCTS
5.2.3.2
HIGH GROWTH POTENTIAL IN EMERGING ECONOMIES
5.2.3.3
GROWING ADOPTION OF DRUG DEVICE COMBINATION PRODUCTS AND EXPANDING BIOLOGICS MARKET
5.2.4.1
HEAVY FINANCIAL IMPACT OF DRUG WASTAGE AND DEVICE MALFUNCTION
5.2.4.2
LACK OF STANDARDIZED REIMBURSEMENT POLICIES
5.2.4.3
LIMITED TRAINING AND EDUCATION FOR HEALTHCARE PROFESSIONALS
5.2.4.4
LACK OF MEDICAL SPECIALISTS AND SURGEONS
5.3.1
RISING POPULARITY OF SELF-ADMINISTERED MEDICINES AND HOME CARE SETTINGS
5.3.2
INTEGRATION OF DRUG DEVICE COMBINATION PRODUCTS WITH SMART CONNECTED DEVICES
5.4.1.1
WEARABLE TECHNOLOGIES
5.4.1.2
DRUG-ELUTING TECHNOLOGIES
5.4.2
COMPLEMENTARY TECHNOLOGIES
5.4.2.1
CONNECTED HEALTH AND DIGITAL TECHNOLOGIES
5.4.3
ADJACENT TECHNOLOGIES
5.4.3.1
ADVANCED MATERIALS AND BIOPOLYMERS
5.5
PORTER’S FIVE FORCES ANALYSIS
5.5.1
THREAT OF NEW ENTRANTS
5.5.2
THREAT OF SUBSTITUTES
5.5.3
BARGAINING POWER OF SUPPLIERS
5.5.4
BARGAINING POWER OF BUYERS
5.5.5
INTENSITY OF COMPETITIVE RIVALRY
5.6
KEY STAKEHOLDERS & BUYING CRITERIA
5.6.1
KEY STAKEHOLDERS IN BUYING PROCESS
5.6.2
KEY BUYING CRITERIA
5.7.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.7.2
REGULATORY FRAMEWORK
5.7.2.5
MIDDLE EAST & AFRICA
5.8.1
KEY PATENTS GRANTED
5.9.1
TRADE ANALYSIS FOR PREFILLED SYRINGES (HS CODE 300431), 2019–2023
5.9.1.1
IMPORT DATA FOR HS CODE 300431
5.9.1.2
EXPORT DATA FOR HS CODE 300431
5.9.2
TRADE DATA FOR TRANSDERMAL PATCHES (HS CODE 300431), 2019–2023
5.9.2.1
IMPORT DATA FOR HS CODE 300431
5.9.2.2
EXPORT DATA FOR HS CODE 300431
5.10.1
INDICATIVE PRICING OF DRUG DEVICE COMBINATION PRODUCTS, BY KEY PLAYER, 2024
5.10.2
AVERAGE SELLING PRICE TREND OF INJECTABLE DRUG DELIVERY DEVICES, BY KEY PLAYER, 2022–2024
5.10.3
AVERAGE SELLING PRICE TREND OF DRUG DELIVERY COMBINATION PRODUCTS, BY REGION, 2022–2024
5.10.3.1
AVERAGE SELLING PRICE TREND FOR PEN INJECTORS, 2022–2024
5.10.3.2
AVERAGE SELLING PRICE TREND FOR INHALERS, 2022–2024
5.10.3.3
AVERAGE SELLING PRICE TREND FOR DRUG-ELUTING STENTS, 2022–2024
5.11
VALUE CHAIN ANALYSIS
5.12
KEY CONFERENCES & EVENTS, 2025–2026
5.13
UNMET NEEDS/END-USER EXPECTATIONS
5.14
ADJACENT MARKET ANALYSIS
5.16.1
MINIMED 780G DIABETES MANAGEMENT SYSTEM TO COMBINE CONTINUOUS GLUCOSE MONITORING WITH AUTOMATED INSULIN DELIVERY
5.16.2
DIGIINHALER-SMART INHALER FOR ASTHMA/COPD TO TRACK LUNG FUNCTION
5.16.3
ADOPTION OF PEN INJECTORS BY NEMERA FRANCE TO IMPROVE THERAPEUTIC OUTCOMES
5.17
SUPPLY CHAIN ANALYSIS
5.18
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.19
INVESTMENT & FUNDING SCENARIO
5.20
REIMBURSEMENT SCENARIO ANALYSIS
5.21
CLINICAL PIPELINE ANALYSIS
5.22
IMPACT OF AI/GEN AI ON DRUG DEVICE COMBINATION PRODUCTS MARKET
5.23
IMPACT OF 2025 US TARIFF ON DRUG DEVICE COMBINATION PRODUCTS MARKET
5.23.2
PRICE IMPACT ANALYSIS
5.23.3
IMPACT ON COUNTRY/REGION
5.23.4
IMPACT ON END-USE INDUSTRIES
5.23.4.1
HOSPITALS & CLINICS
5.23.4.2
AMBULATORY SURGERY CENTERS
5.23.4.3
LONG-TERM CARE FACILITIES
5.23.4.4
HOME CARE SETTINGS
6
DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Billion | 25 Data Tables
108
6.2
INJECTABLE DRUG DELIVERY DEVICES
6.2.1.1
NEED TO ELIMINATE DOSING MISTAKES AND IMPROVE PATIENT COMPLIANCE TO DRIVE SEGMENT
6.2.2.1
EASE OF SELF-ADMINISTRATION AND IMPROVED DOSAGE ACCURACY TO FUEL ADOPTION
6.2.3.1
EASE OF USE AND BETTER PATIENT EXPERIENCE TO AID ADOPTION IN EMERGENCY MEDICAL CONDITIONS
6.2.4.1
RISING POPULARITY OF EMBEDDED WIRELESS DEVICES TO PROPEL MARKET GROWTH
6.2.5
NEEDLE-FREE INJECTORS
6.2.5.1
REDUCED RISK OF NEEDLESTICK INJURY TO FUEL MARKET ADOPTION
6.3.1
LOW RATE OF RESTENOSIS TO PROPEL MARKET GROWTH
6.4.1
INCREASING PREVALENCE OF RESPIRATORY DISEASES TO FUEL UPTAKE
6.5.1
RISING NUMBER OF SURGICAL PROCEDURES TO FUEL DEMAND FOR AMBULATORY INFUSION PUMPS
6.6.1
RISING INCIDENCE OF CHRONIC DISEASES REQUIRING LONG-TERM MEDICATION TO AID MARKET GROWTH
6.7.1
ABILITY TO DELIVER LOCALIZED DRUG THERAPY WITH MINIMAL SYSTEMIC EXPOSURE TO DRIVE MARKET
7
DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION
Market Size & Growth Rate Forecast Analysis to 2030 in USD Billion | 14 Data Tables
133
7.2.1
HIGH GERIATRIC POPULATION AND INCREASED SEDENTARY LIFESTYLE TO PROPEL MARKET GROWTH
7.3.1
RISE IN URBANIZATION, AIR POLLUTION, AND SMOKING TO FUEL RESPIRATORY AILMENTS
7.4.1
RISE OF DIABETIC EYE DISEASES AND FAVORABLE REGULATORY SCENARIO TO AUGMENT MARKET GROWTH
7.5.1
NEED FOR PROLONGED TREATMENT IN CHRONIC PATIENTS TO SPUR MARKET GROWTH
7.6.1
DRUG DEVICE COMBINATION PRODUCTS TO AID THERAPEUTIC PRECISION AND OPTIMIZE PATIENT OUTCOMES DURING CANCER TREATMENT
7.7.1
IRREGULARIZED URBANIZATION AND POOR SANITATION IN EMERGING ECONOMIES TO PROPEL MARKET GROWTH
7.8
CARDIOVASCULAR DISEASES
7.8.1
INCREASE IN SEDENTARY LIFESTYLE AND CHANGES IN EATING HABITS TO FUEL MARKET GROWTH
7.9.1
INCREASING PREVALENCE OF OBESITY TO SUPPORT MARKET GROWTH
7.10.1
BETTER PATIENT ADHERENCE AND MINIMAL SIDE EFFECTS TO DRIVE ADOPTION OF TRANSDERMAL PATCHES
8
DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2030 in USD Billion | 6 Data Tables
152
8.2.1
ACCESS TO MULTI-DISCIPLINARY EXPERTISE AND PROCEDURE-BASED CARE TO AID MARKET GROWTH
8.3
AMBULATORY SURGERY CENTERS
8.3.1
NEED FOR COST-EFFECTIVE AND HIGH-QUALITY MINIMALLY INVASIVE TREATMENT TO SUPPORT MARKET GROWTH
8.4
LONG-TERM CARE FACILITIES
8.4.1
INCREASING INCIDENCE OF CHRONIC DISEASES AMONG ELDERLY AND DISABLED POPULATION TO DRIVE MARKET
8.5.1
INCREASING DEMAND FOR PATIENT-CENTRIC AND COST-EFFECTIVE HEALTHCARE TO PROPEL MARKET GROWTH
9
DRUG DEVICE COMBINATION PRODUCTS MARKET, BY REGION
Comprehensive coverage of 8 Regions with country-level deep-dive of 16 Countries | 131 Data Tables.
163
9.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
9.2.2.1
US TO DOMINATE NORTH AMERICAN DRUG DEVICE COMBINATION PRODUCTS MARKET DURING FORECAST PERIOD
9.2.3.1
REGULATORY MODERNIZATION AND STRATEGIC GOVERNMENT INVESTMENTS TO AUGMENT MARKET GROWTH
9.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
9.3.2.1
TECHNOLOGICAL ADVANCEMENTS AND STRONG R&D INFRASTRUCTURE TO PROPEL MARKET GROWTH
9.3.3.1
STRONG EMPHASIS ON PERSONALIZED AND VALUE-BASED HEALTHCARE TO AID MARKET GROWTH
9.3.4.1
STRONG HEALTHCARE INFRASTRUCTURE AND HIGH INVESTMENTS IN BIOPHARMACEUTICAL INNOVATION TO BOOST MARKET GROWTH
9.3.5.1
FOCUS ON PHARMACEUTICAL-MEDITECH CONVERGENCE AND HEALTHCARE MODERNIZATION TO DRIVE MARKET
9.3.6.1
INCREASING GERIATRIC POPULATION AND GROWING FOCUS ON HOME-BASED TREATMENT TO PROPEL MARKET GROWTH
9.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
9.4.2.1
FAVORABLE GOVERNMENT POLICIES AND INCREASED HEALTHCARE SPENDING TO SUPPORT MARKET GROWTH
9.4.3.1
ADVANCED HEALTHCARE SYSTEMS AND UNIVERSAL REIMBURSEMENT POLICIES TO SPUR MARKET GROWTH
9.4.4.1
GROWING FOCUS ON DIGITAL HEALTH INTEGRATION AND BOOMING BIOSIMILARS SECTOR TO DRIVE MARKET
9.4.5.1
ROBUST R&D INFRASTRUCTURE AND ENHANCED FOCUS ON GOVERNMENT-INDUSTRY COLLABORATIONS TO AID MARKET GROWTH
9.4.6.1
RISING HEALTHCARE INVESTMENTS BY GOVERNMENT AND PRIVATE ORGANIZATIONS TO BOOST MARKET GROWTH
9.4.7
REST OF ASIA PACIFIC
9.5.1
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
9.5.2.1
PRESENCE OF UNIVERSAL HEALTHCARE SYSTEM AND HIGH GERIATRIC POPULATION TO DRIVE MARKET
9.5.3.1
FOCUS ON NEARSHORING AND IMPROVEMENT IN HEALTHCARE SECTOR TO DRIVE MARKET
9.5.4
REST OF LATIN AMERICA
9.6.1
MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
9.6.2.1
KINGDOM OF SAUDI ARABIA
9.6.2.3
REST OF GCC COUNTRIES
9.6.3
REST OF MIDDLE EAST & AFRICA
10
COMPETITIVE LANDSCAPE
Discover market leaders' winning strategies and emerging competitors in drug device combination products.
242
10.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
10.2.1
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG DEVICE COMBINATION PRODUCTS MARKET
10.3
REVENUE ANALYSIS, 2020–2024
10.4
MARKET SHARE ANALYSIS, 2024
10.4.1
RANKING OF KEY MARKET PLAYERS
10.5
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
10.5.5
COMPANY FOOTPRINT: KEY PLAYERS, 2024
10.5.5.1
COMPANY FOOTPRINT
10.5.5.2
REGION FOOTPRINT
10.5.5.3
PRODUCT TYPE FOOTPRINT
10.5.5.4
APPLICATION FOOTPRINT
10.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
10.6.1
PROGRESSIVE COMPANIES
10.6.2
RESPONSIVE COMPANIES
10.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
10.6.5.1
DETAILED LIST OF KEY STARTUPS/SME PLAYERS
10.6.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS
10.7
COMPANY VALUATION & FINANCIAL METRICS
10.8
BRAND/PRODUCT COMPARISON
10.9
COMPETITIVE SCENARIO
10.9.1
PRODUCT LAUNCHES AND APPROVALS
10.9.4
OTHER DEVELOPMENTS
11
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
266
11.1.1.1
BUSINESS OVERVIEW
11.1.1.2
PRODUCTS OFFERED
11.1.1.3
RECENT DEVELOPMENTS
11.1.2
ELI LILLY AND COMPANY
11.1.7
BOSTON SCIENTIFIC CORPORATION
11.1.8
BECTON, DICKINSON AND COMPANY
11.1.11
TEVA PHARMACEUTICAL INDUSTRIES LTD.
11.1.14
TERUMO CORPORATION
11.2.1
TANDEM DIABETES CARE, INC.
11.2.3
INTARCIA THERAPEUTICS, INC.
11.2.6
LEAD CHEMICAL CO., LTD.
11.2.7
PURDUE PHARMA L.P.
11.2.10
MUNDIPHARMA INTERNATIONAL LIMITED
11.2.11
SPARSHA PHARMA INTERNATIONAL PVT. LTD.
11.2.12
SUPERNUS PHARMACEUTICALS, INC.
12.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3
CUSTOMIZATION OPTIONS
TABLE 1
DRUG DEVICE COMBINATION PRODUCTS MARKET: INCLUSIONS & EXCLUSIONS
TABLE 2
EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
TABLE 3
DRUG DEVICE COMBINATION PRODUCTS MARKET: STUDY ASSUMPTIONS
TABLE 4
DRUG DEVICE COMBINATION PRODUCTS MARKET: RISK ANALYSIS
TABLE 5
DIABETES POPULATION WORLDWIDE, 2024 VS. 2050 (MILLION)
TABLE 6
DRUG DEVICE COMBINATION PRODUCTS MARKET: PORTER’S FIVE FORCES
TABLE 7
INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF DRUG DEVICE COMBINATION PRODUCTS
TABLE 8
KEY BUYING CRITERIA FOR DRUG DEVICE COMBINATION PRODUCTS
TABLE 9
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12
LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13
MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14
US: CLASSIFICATION AND APPROVAL PATHWAYS
TABLE 15
US: CLASSIFICATION OF MEDICAL EQUIPMENT
TABLE 16
US: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
TABLE 17
CANADA: CLASSIFICATION OF DRUG DEVICE COMBINATION PRODUCTS
TABLE 18
CANADA: RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
TABLE 19
EUROPE: EUROPEAN REGULATORY FRAMEWORK FOR DRUG DEVICE COMBINATION PRODUCTS
TABLE 20
EUROPE: RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
TABLE 21
CHINA: RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
TABLE 22
JAPAN: RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
TABLE 23
DRUG DEVICE COMBINATION PRODUCTS MARKET: KEY PATENTS GRANTED, JANUARY 2022−APRIL 2025
TABLE 24
IMPORT DATA FOR PREFILLED SYRINGES (HS CODE 300431), BY COUNTRY, 2019–2023 (USD THOUSAND)
TABLE 25
EXPORT DATA FOR PREFILLED SYRINGES (HS CODE 300431), BY COUNTRY, 2019–2023 (USD THOUSAND)
TABLE 26
IMPORTS DATA FOR TRANSDERMAL PATCHES (HS CODE 300431), BY COUNTRY, 2019–2023 (USD THOUSAND)
TABLE 27
EXPORT DATA FOR TRANSDERMAL PATCHES (HS CODE 300431), BY COUNTRY, 2019–2023 (USD THOUSAND)
TABLE 28
INDICATIVE PRICING OF DRUG DEVICE COMBINATION PRODUCTS, BY KEY PLAYER, 2024
TABLE 29
AVERAGE SELLING PRICE TREND OF INJECTABLE DRUG DEVICE DELIVERY DEVICES, BY KEY PLAYER, 2022–2024
TABLE 30
AVERAGE SELLING PRICE TREND FOR PEN INJECTORS, BY REGION, 2022–2024
TABLE 31
AVERAGE SELLING PRICE TREND FOR INHALERS, BY REGION, 2022–2024
TABLE 32
AVERAGE SELLING PRICE TREND FOR DRUG-ELUTING STENTS, BY REGION, 2022–2024
TABLE 33
DRUG DEVICE COMBINATION PRODUCTS MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026
TABLE 34
DRUG DEVICE COMBINATION PRODUCTS MARKET: ROLE IN ECOSYSTEM
TABLE 35
CASE STUDY 1: MINIMED 780G DIABETES MANAGEMENT SYSTEM TO COMBINE CONTINUOUS GLUCOSE MONITORING WITH AUTOMATED INSULIN DELIVERY
TABLE 36
CASE STUDY 2: DIGIINHALER-SMART INHALER FOR ASTHMA/COPD TO TRACK LUNG FUNCTION
TABLE 37
CASE STUDY 3: ADOPTION OF PEN INJECTORS BY NEMERA FRANCE TO IMPROVE THERAPEUTIC OUTCOMES
TABLE 38
DRUG DEVICE COMBINATION PRODUCTS MARKET: REIMBURSEMENT SCENARIO ANALYSIS
TABLE 39
DRUG DEVICE COMBINATION PRODUCTS MARKET: CLINICAL PIPELINE ANALYSIS (AS OF MARCH 2025)
TABLE 40
US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 41
KEY PRODUCT-RELATED TARIFF FOR DRUG DEVICE PRODUCTS
TABLE 42
DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
TABLE 43
DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 44
DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 45
LIST OF KEY PREFILLED SYRINGES AVAILABLE IN MARKET
TABLE 46
PREFILLED SYRINGES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 47
LAUNCH OF KEY GLP-1-RELATED INJECTABLES BY MAJOR PHARMACEUTICAL COMPANIES, 2010–2024
TABLE 48
LIST OF KEY PEN INJECTORS AVAILABLE IN MARKET
TABLE 49
PEN INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 50
LIST OF KEY AUTOINJECTORS AVAILABLE IN MARKET
TABLE 51
AUTOINJECTORS MARKET, BY COUNTRY 2023–2030 (USD BILLION)
TABLE 52
TOP FIVE COUNTRIES WITH HIGHEST NUMBER OF DIABETES PATIENTS (20–79 YEARS), 2021 VS. 2045 (MILLION)
TABLE 53
LIST OF KEY WEREABLE INJECTORS AVAILABLE IN MARKET
TABLE 54
WEARABLE INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 55
LIST OF KEY NEEDLE-FREE INJECTORS AVAILABLE IN MARKET
TABLE 56
NEEDLE-FREE INJECTORS MARKET, BY COUNTRY 2023–2030 (USD BILLION)
TABLE 57
DRUG DEVICE COMBINATION PRODUCTS MARKET FOR DRUG-ELUTING STENTS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 58
LIST OF KEY INHALERS AVAILABLE IN MARKET
TABLE 59
DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INHALERS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 60
LIST OF KEY INFUSION PUMPS AVAILABLE IN MARKET
TABLE 61
DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INFUSION PUMPS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 62
LIST OF KEY TRANSDERMAL PATCHES AVAILABLE IN MARKET
TABLE 63
DRUG DEVICE COMBINATION PRODUCTS MARKET FOR TRANSDERMAL PATCHES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 64
LIST OF KEY DRUG-COATED BALLOONS AVAILABLE IN MARKET
TABLE 65
DRUG DEVICE COMBINATION PRODUCTS MARKET FOR DRUG-COATED BALLOONS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 66
DRUG DEVICE COMBINATION PRODUCTS MARKET FOR OTHER PRODUCT TYPES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 67
DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
TABLE 68
DRUG DEVICE COMBINATION PRODUCTS MARKET FOR DIABETES MANAGEMENT, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 69
DRUG DEVICE COMBINATION PRODUCTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 70
DRUG DEVICE COMBINATION PRODUCTS MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 71
DRUG DEVICE COMBINATION PRODUCTS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 72
DRUG DEVICE COMBINATION PRODUCTS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 73
KEY DRUG DEVICE COMBINATION PRODUCTS AVAILABLE FOR INFECTIOUS DISEASES
TABLE 74
DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 75
DRUG DEVICE COMBINATION PRODUCTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 76
KEY DRUG DEVICE COMBINATION PRODUCTS AVAILABLE FOR OBESITY MANAGEMENT
TABLE 77
DRUG DEVICE COMBINATION PRODUCTS MARKET FOR OBESITY MANAGEMENT, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 78
KEY TRANSDERMAL PATCHES AVAILABLE FOR PAIN MANAGEMENT
TABLE 79
DRUG DEVICE COMBINATION PRODUCTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 80
DRUG DEVICE COMBINATION PRODUCTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 81
DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 82
DRUG DEVICE COMBINATION PRODUCTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 83
DRUG DEVICE COMBINATION PRODUCTS MARKET FOR AMBULATORY SURGERY CENTERS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 84
DRUG DEVICE COMBINATION PRODUCTS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 85
DRUG DEVICE COMBINATION PRODUCTS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 86
DRUG DEVICE COMBINATION PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 87
DRUG DEVICE COMBINATION PRODUCTS MARKET, BY REGION, 2023–2030 (USD BILLION)
TABLE 88
TRANSDERMAL PATCHES MARKET, BY REGION, 2023–2030 (THOUSAND UNITS)
TABLE 89
DRUG-ELUTING STENTS MARKET, BY REGION, 2023–2030 (THOUSAND UNITS)
TABLE 90
NORTH AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 91
NORTH AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
TABLE 92
NORTH AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 93
NORTH AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
TABLE 94
NORTH AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 95
US: KEY MACROINDICATORS
TABLE 96
US: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
TABLE 97
US: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 98
US: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
TABLE 99
US: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 100
CANADA: KEY MACROINDICATORS
TABLE 101
CANADA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
TABLE 102
CANADA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 103
CANADA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
TABLE 104
CANADA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 105
EUROPE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 106
EUROPE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
TABLE 107
EUROPE: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 108
EUROPE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
TABLE 109
EUROPE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 110
GERMANY: KEY MACROINDICATORS
TABLE 111
GERMANY: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
TABLE 112
GERMANY: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 113
GERMANY: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
TABLE 114
GERMANY: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 115
UK: KEY MACROINDICATORS
TABLE 116
UK: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
TABLE 117
UK: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 118
UK: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
TABLE 119
UK: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 120
FRANCE: KEY MACROINDICATORS
TABLE 121
FRANCE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
TABLE 122
FRANCE: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 123
FRANCE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
TABLE 124
FRANCE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 125
ITALY: KEY MACROINDICATORS
TABLE 126
ITALY: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
TABLE 127
ITALY: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 128
ITALY: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
TABLE 129
ITALY: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 130
SPAIN: KEY MACROINDICATORS
TABLE 131
SPAIN: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
TABLE 132
SPAIN: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 133
SPAIN: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
TABLE 134
SPAIN: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 135
REST OF EUROPE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
TABLE 136
REST OF EUROPE: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 137
REST OF EUROPE: DRUG DEVICE COMBINATION PRODUCTS MARKET, APPLICATION, 2023–2030 (USD BILLION)
TABLE 138
REST OF EUROPE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 139
ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 140
ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
TABLE 141
ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 142
ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
TABLE 143
ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 144
CHINA: KEY MACROINDICATORS
TABLE 145
CHINA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
TABLE 146
CHINA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 147
CHINA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
TABLE 148
CHINA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 149
JAPAN: KEY MACROINDICATORS
TABLE 150
JAPAN: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
TABLE 151
JAPAN: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 152
JAPAN: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
TABLE 153
JAPAN: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 154
INDIA: KEY MACROINDICATORS
TABLE 155
INDIA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
TABLE 156
INDIA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 157
INDIA: DRUG DEVICE COMBINATION PRODUCTS MARKET, APPLICATION, 2023–2030 (USD BILLION)
TABLE 158
INDIA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 159
SOUTH KOREA: KEY MACROINDICATORS
TABLE 160
SOUTH KOREA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
TABLE 161
SOUTH KOREA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 162
SOUTH KOREA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
TABLE 163
SOUTH KOREA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 164
AUSTRALIA: KEY MACROINDICATORS
TABLE 165
AUSTRALIA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
TABLE 166
AUSTRALIA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 167
AUSTRALIA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
TABLE 168
AUSTRALIA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 169
REST OF ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
TABLE 170
REST OF ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 171
REST OF ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
TABLE 172
REST OF ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 173
LATIN AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 174
LATIN AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
TABLE 175
LATIN AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 176
LATIN AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
TABLE 177
LATIN AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 178
BRAZIL: KEY MACROINDICATORS
TABLE 179
BRAZIL: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
TABLE 180
BRAZIL: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 181
BRAZIL: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
TABLE 182
BRAZIL: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 183
MEXICO: KEY MACROINDICATORS
TABLE 184
MEXICO: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
TABLE 185
MEXICO: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 186
MEXICO: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
TABLE 187
MEXICO: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 188
REST OF LATIN AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
TABLE 189
REST OF LATIN AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 190
REST OF LATIN AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
TABLE 191
REST OF LATIN AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 192
MIDDLE EAST & AFRICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY REGION, 2023–2030 (USD BILLION)
TABLE 193
MIDDLE EAST & AFRICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
TABLE 194
MIDDLE EAST & AFRICA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 195
MIDDLE EAST & AFRICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
TABLE 196
MIDDLE EAST & AFRICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 197
GCC COUNTRIES: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 198
GCC COUNTRIES: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
TABLE 199
GCC COUNTRIES: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 200
GCC COUNTRIES: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
TABLE 201
GCC COUNTRIES: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 202
KINGDOM OF SAUDI ARABIA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
TABLE 203
KINGDOM OF SAUDI ARABIA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 204
KINGDOM OF SAUDI ARABIA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
TABLE 205
KINGDOM OF SAUDI ARABIA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 206
UAE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
TABLE 207
UAE: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 208
UAE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
TABLE 209
UAE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 210
REST OF GCC COUNTRIES: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
TABLE 211
REST OF GCC COUNTRIES: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 212
REST OF GCC COUNTRIES: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
TABLE 213
REST OF GCC COUNTRIES: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 214
REST OF MIDDLE EAST & AFRICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
TABLE 215
REST OF MIDDLE EAST & AFRICA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 216
REST OF MIDDLE EAST & AFRICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
TABLE 217
REST OF MIDDLE EAST & AFRICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 218
OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN DRUG DEVICE COMBINATION PRODUCTS MARKET
TABLE 219
DRUG DEVICE COMBINATION PRODUCTS MARKET FOR AUTOINJECTORS: DEGREE OF COMPETITION
TABLE 220
DRUG DEVICE COMBINATION PRODUCTS MARKET FOR PEN INJECTORS: DEGREE OF COMPETITION
TABLE 221
DRUG DEVICE COMBINATION PRODUCTS MARKET FOR TRANSDERMAL PATCHES: DEGREE OF COMPETITION
TABLE 222
DRUG DEVICE COMBINATION PRODUCTS MARKET: REGION FOOTPRINT
TABLE 223
DRUG DEVICE COMBINATION PRODUCTS MARKET: PRODUCT TYPE FOOTPRINT
TABLE 224
DRUG DEVICE COMBINATION PRODUCTS MARKET: APPLICATION FOOTPRINT
TABLE 225
DRUG DEVICE COMBINATION PRODUCTS MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS
TABLE 226
DRUG DEVICE COMBINATION PRODUCTS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS
TABLE 227
DRUG DEVICE COMBINATION PRODUCTS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
TABLE 228
DRUG DEVICE COMBINATION PRODUCTS MARKET: DEALS, JANUARY 2022–MARCH 2025
TABLE 229
DRUG DEVICE COMBINATION PRODUCTS MARKET: EXPANSIONS, JANUARY 2022–MARCH 2025
TABLE 230
DRUG DEVICE COMBINATION PRODUCTS MARKET: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025
TABLE 231
ABBOTT: COMPANY OVERVIEW
TABLE 232
ABBOTT: PRODUCTS OFFERED
TABLE 233
ABBOTT: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
TABLE 234
ABBOTT: DEALS, JANUARY 2022–MARCH 2025
TABLE 235
ELI LILLY AND COMPANY: COMPANY OVERVIEW
TABLE 236
ELI LILLY AND COMPANY: PRODUCTS OFFERED
TABLE 237
ELI LILLY AND COMPANY: PRODUCT APPROVALS, JANUARY 2022–MARCH 2025
TABLE 238
ELI LILLY AND COMPANY: DEALS, JANUARY 2022–MARCH 2025
TABLE 239
ELI LILLY AND COMPANY: EXPANSIONS, JANUARY 2022–MARCH 2025
TABLE 240
ELI LILLY AND COMPANY: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025
TABLE 241
MEDTRONIC: COMPANY OVERVIEW
TABLE 242
MEDTRONIC: PRODUCTS OFFERED
TABLE 243
MEDTRONIC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
TABLE 244
MEDTRONIC: DEALS, JANUARY 2022–MARCH 2025
TABLE 245
NOVO NORDISK A/S: COMPANY OVERVIEW
TABLE 246
NOVO NORDISK A/S: PRODUCTS OFFERED
TABLE 247
NOVO NORDISK A/S: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
TABLE 248
NOVO NORDISK A/S: DEALS, JANUARY 2022–MARCH 2025
TABLE 249
NOVO NORDISK A/S: EXPANSIONS, JANUARY 2022–MARCH 2025
TABLE 250
NOVARTIS AG: COMPANY OVERVIEW
TABLE 251
NOVARTIS AG: PRODUCTS OFFERED
TABLE 252
NOVARTIS AG: PRODUCT APPROVALS, JANUARY 2022–MARCH 2025
TABLE 253
NOVARTIS AG: DEALS, JANUARY 2022–MARCH 2025
TABLE 254
NOVARTIS AG: EXPANSIONS, JANUARY 2022–MARCH 2025
TABLE 255
SANOFI: COMPANY OVERVIEW
TABLE 256
SANOFI: PRODUCTS OFFERED
TABLE 257
SANOFI: PRODUCT APPROVALS, JANUARY 2022–MARCH 2025
TABLE 258
SANOFI: DEALS, JANUARY 2022–MARCH 2025
TABLE 259
SANOFI: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025
TABLE 260
BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW
TABLE 261
BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED
TABLE 262
BOSTON SCIENTIFIC CORPORATION: PRODUCT APPROVALS, JANUARY 2022–MARCH 2025
TABLE 263
BOSTON SCIENTIFIC CORPORATION: DEALS, JANUARY 2022–MARCH 2025
TABLE 264
BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
TABLE 265
BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED
TABLE 266
BECTON, DICKINSON AND COMPANY: DEALS, JANUARY 2022–MARCH 2025
TABLE 267
BECTON, DICKINSON AND COMPANY: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025
TABLE 268
MERCK KGAA: COMPANY OVERVIEW
TABLE 269
MERCK KGAA: PRODUCTS OFFERED
TABLE 270
MERCK KGGA: DEALS, JANUARY 2022–MARCH 2025
TABLE 271
ABBVIE INC.: COMPANY OVERVIEW
TABLE 272
ABBVIE INC.: PRODUCTS OFFERED
TABLE 273
ABBVIE INC: PRODUCT APPROVALS, JANUARY 2022–MARCH 2025
TABLE 274
ABBVIE INC.: DEALS, JANUARY 2022–MARCH 2025
TABLE 275
ABBVIE INC.: EXPANSIONS, JANUARY 2022–MARCH 2025
TABLE 276
TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
TABLE 277
TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
TABLE 278
TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT APPROVALS, JANUARY 2022–MARCH 2025
TABLE 279
TEVA PHARMACEUTICAL INDUSTRIES LTD.: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025
TABLE 280
STRYKER: COMPANY OVERVIEW
TABLE 281
STRYKER: PRODUCTS OFFERED
TABLE 282
B. BRAUN SE: COMPANY OVERVIEW
TABLE 283
B. BRAUN SE: PRODUCTS OFFERED
TABLE 284
TERUMO CORPORATION: COMPANY OVERVIEW
TABLE 285
TERUMO CORPORATION: PRODUCTS OFFERED
TABLE 286
TERUMO CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
TABLE 287
TANDEM DIABETES CARE, INC.: COMPANY OVERVIEW
TABLE 288
CEQUR SIMPLICITY: COMPANY OVERVIEW
TABLE 289
INTARCIA THERAPEUTICS, INC.: COMPANY OVERVIEW
TABLE 290
HALOZYME, INC.: COMPANY OVERVIEW
TABLE 291
KALEO, INC.: COMPANY OVERVIEW
TABLE 292
LEAD CHEMICAL CO., LTD.: COMPANY OVERVIEW
TABLE 293
PURDUE PHARMA L.P.: COMPANY OVERVIEW
TABLE 294
ALVOGEN: COMPANY OVERVIEW
TABLE 295
EVOLUTIS: COMPANY OVERVIEW
TABLE 296
MUNDIPHARMA INTERNATIONAL LIMITED: COMPANY OVERVIEW
TABLE 297
SPARSHA PHARMA INTERNATIONAL PVT. LTD.: COMPANY OVERVIEW
TABLE 298
SUPERNUS PHARMACEUTICALS, INC.: COMPANY OVERVIEW
TABLE 299
ALCON INC.: COMPANY OVERVIEW
FIGURE 1
DRUG DEVICE COMBINATION PRODUCTS MARKET: SEGMENTS CONSIDERED & GEOGRAPHICAL SCOPE
FIGURE 2
DRUG DEVICE COMBINATION PRODUCTS MARKET: YEARS CONSIDERED
FIGURE 3
DRUG DEVICE COMBINATION PRODUCTS MARKET: RESEARCH DESIGN
FIGURE 4
DRUG DEVICE COMBINATION PRODUCTS MARKET: KEY DATA FROM SECONDARY SOURCES
FIGURE 5
DRUG DEVICE COMBINATION PRODUCTS MARKET: KEY PRIMARY SOURCES
FIGURE 6
DRUG DEVICE COMBINATION PRODUCTS MARKET: INSIGHTS FROM PRIMARIES
FIGURE 7
DRUG DEVICE COMBINATION PRODUCTS MARKET: BREAKDOWN OF PRIMARIES (BY COMPANY TYPE, DESIGNATION, AND REGION)
FIGURE 8
DRUG DEVICE COMBINATION PRODUCTS MARKET: BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY- AND DEMAND-SIDE PARTICIPANTS)
FIGURE 9
DRUG DEVICE COMBINATION PRODUCTS MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS (2024)
FIGURE 10
PEN INJECTORS MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (BOTTOM-UP APPROACH)
FIGURE 11
AUTOINJECTORS MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (BOTTOM-UP APPROACH)
FIGURE 12
DRUG DEVICE COMBINATION PRODUCTS MARKET: TOP-DOWN APPROACH
FIGURE 13
DRUG DEVICE COMBINATION PRODUCTS MARKET: CAGR PROJECTIONS (SUPPLY SIDE)
FIGURE 14
DRUG DEVICE COMBINATION PRODUCTS MARKET: DATA TRIANGULATION
FIGURE 15
DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2025 VS. 2030 (USD BILLION)
FIGURE 16
DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2025 VS. 2030 (USD BILLION)
FIGURE 17
DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2025 VS. 2030 (USD BILLION)
FIGURE 18
DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2025 VS. 2030 (USD BILLION)
FIGURE 19
REGIONAL SNAPSHOT OF DRUG DEVICE COMBINATION PRODUCTS MARKET
FIGURE 20
INCREASING NUMBER OF REGULATORY APPROVALS AND RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET
FIGURE 21
CHINA AND DIABETES MANAGEMENT SEGMENT COMMANDED LARGEST MARKET SHARE IN 2024
FIGURE 22
CHINA TO REGISTER HIGHEST CAGR FROM 2025 TO 2030
FIGURE 23
DRUG DEVICE COMBINATION PRODUCTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 24
DISABILITY-ADJUSTED LIFE YEARS FOR INDIVIDUALS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN AUSTRALIA, BY AGE (2023)
FIGURE 25
SHARE OF GLOBAL GERIATRIC POPULATION (ABOVE 60 YEARS), BY REGION, 2010 VS. 2015 VS. 2030 (PROJECTED)
FIGURE 26
DRUG DEVICE COMBINATION PRODUCTS MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 27
INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF DRUG DEVICE COMBINATION PRODUCTS
FIGURE 28
KEY BUYING CRITERIA FOR DRUG DEVICE COMBINATION PRODUCTS
FIGURE 29
DRUG DEVICE COMBINATION PRODUCTS MARKET: PATENT PUBLICATION TRENDS AND TOP APPLICANT ANALYSIS (JANUARY 2014–APRIL 2025)
FIGURE 30
TOP PATENT APPLICANTS FOR DRUG DEVICE COMBINATION PRODUCTS, BY JURISDICTION (JANUARY 2014–APRIL 2025)
FIGURE 31
DRUG DEVICE COMBINATION PRODUCTS MARKET: VALUE CHAIN ANALYSIS
FIGURE 32
DRUG DEVICE COMBINATION PRODUCTS MARKET: ADJACENT MARKETS
FIGURE 33
DRUG DEVICE COMBINATION PRODUCTS MARKET: ECOSYSTEM ANALYSIS
FIGURE 34
DRUG DEVICE COMBINATION PRODUCTS MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 35
DRUG DEVICE COMBINATION PRODUCTS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 36
DRUG DEVICE COMBINATION PRODUCTS MARKET: FUNDING AND NUMBER OF DEALS, 2019–2023
FIGURE 37
DRUG DEVICE COMBINATION PRODUCTS MARKET: IMPACT OF AI/GEN AI
FIGURE 38
NORTH AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET SNAPSHOT
FIGURE 39
ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET SNAPSHOT
FIGURE 40
REVENUE ANALYSIS OF KEY PLAYERS IN DRUG DEVICE COMBINATION PRODUCTS MARKET (2020–2024)
FIGURE 41
MARKET SHARE ANALYSIS OF KEY PLAYERS IN AUTOINJECTORS MARKET (2024)
FIGURE 42
MARKET SHARE ANALYSIS OF KEY PLAYERS IN PEN INJECTORS MARKET (2024)
FIGURE 43
MARKET SHARE ANALYSIS OF KEY PLAYERS IN TRANSDERMAL PATCHES MARKET (2024)
FIGURE 44
RANKING OF KEY PLAYERS IN DRUG DEVICE COMBINATION PRODUCTS MARKET (2024)
FIGURE 45
DRUG DEVICE COMBINATION PRODUCTS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
FIGURE 46
DRUG DEVICE COMBINATION PRODUCTS MARKET: COMPANY FOOTPRINT
FIGURE 47
DRUG DEVICE COMBINATION PRODUCTS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
FIGURE 48
EV/EBITDA OF KEY VENDORS
FIGURE 49
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 50
DRUG DEVICE COMBINATION PRODUCTS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 51
ABBOTT: COMPANY SNAPSHOT
FIGURE 52
ELI LILLY AND COMPANY: COMPANY SNAPSHOT
FIGURE 53
MEDTRONIC: COMPANY SNAPSHOT
FIGURE 54
NOVO NORDISK A/S: COMPANY SNAPSHOT
FIGURE 55
NOVARTIS AG: COMPANY SNAPSHOT
FIGURE 56
SANOFI: COMPANY SNAPSHOT
FIGURE 57
BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
FIGURE 58
BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
FIGURE 59
MERCK KGAA: COMPANY SNAPSHOT
FIGURE 60
ABBVIE INC.: COMPANY SNAPSHOT
FIGURE 61
TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
FIGURE 62
STRYKER: COMPANY SNAPSHOT
FIGURE 63
B. BRAUN SE: COMPANY SNAPSHOT
FIGURE 64
TERUMO CORPORATION: COMPANY SNAPSHOT
Growth opportunities and latent adjacency in Drug Device Combination Products Market